- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 1,116
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol (CZP)
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 98 more
- Conditions
- Migraine Headache
- Interventions
- Placebo, Zolmitriptan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 1,653 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fresno, California • Fullerton, California + 43 more
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
- Procedure · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 883
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
- Interventions
- TORL-1-23, Pegfilgrastim (drug)
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,082 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 71
- States / cities
- Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
- Conditions
- Colorectal Neoplasms
- Interventions
- Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 989
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more
- Conditions
- High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma
- Interventions
- Pazopanib, Pazopanib Hydrochloride, Sapanisertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 460
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more
- Conditions
- Influenza
- Interventions
- MK-1406, Placebo
- Combination Product
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 107 more
- Conditions
- Intermittent Exotropia
- Interventions
- Overminus treatment, Non-overminus treatment
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Fullerton, California • Rochester, Minnesota
- Conditions
- Sjogren's Syndrome
- Interventions
- Placebo, Nipocalimab, Standard of Care Treatment
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2025
- U.S. locations
- 1259
- States / cities
- Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
- Conditions
- Asthma
- Interventions
- AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 21
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Interventions
- TORL-1-23
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 491
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 680
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
- Conditions
- Keratoconus
- Interventions
- Riboflavin drops
- Drug
- Lead sponsor
- Nvision Laser Eye Centers
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 11
- States / cities
- Camarillo, California • Citrus Heights, California • Fullerton, California + 8 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 37
- States / cities
- Berkeley, California • Fullerton, California • Rancho Mirage, California + 31 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 858
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 554 more
- Conditions
- Amblyopia
- Interventions
- Atropine, Plano Lens
- Drug · Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Fullerton, California • Dallas, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab, Placebo
- Drug
- Lead sponsor
- R-Pharm International, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Vincristine, Rescue medication, Methylprednisolone
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,046 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 61
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 56 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,026 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 192
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 170 more